In the Matter of Efamol Nutraceuticals Inc. (2000) , File No. 992 3027

Efamol manufactured and distributed products that it claimed could treat ADHD in children. The FTC claimed that Efamol did not have any reliable scientific evidence to back up its claims.


Efamol claimed that two of its products could treat ADHD symptoms in children by managing fatty acid deficiencies. The FTC filed a complaint alleging that reliable scientific evidence did not exist that supported such a claim, in violation of the Federal Trade Commission Act. Efamol agreed to cease advertising that its products were effective at treating ADHD unless it could produce competent and reliable evidence that supported the company’s claim. In exchange for the voluntary cessation of the subject advertising, the FTC agreed to withdraw its complaint.

The full case and consent order is also available at:

LOADING PDF: If there are any problems, click here to download the file.

Reference Info:Federal, Federal Circuit | United States

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Babener & Associates | Attorney Advertising

Written by:


Babener & Associates on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.